NCT06226090 - A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity | Biotech Hunter

Enrollment

314

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

September 26, 2024

Study Completion Date

October 24, 2024

Conditions

ObesityOverweight

Interventions

DRUG

TG103 7.5 mg

Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.

DRUG

Placebo 7.5 mg

Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.

DRUG

TG103 15 mg

Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

DRUG

Placebo 15 mg

Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

DRUG

TG103 22.5 mg

Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

DRUG

Placebo 22.5 mg

Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

Trial Locations (1)

Clinical Trials Information Group, Shijiazhuang

All Listed Sponsors

lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY